Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In the international randomised phase 3 CORRECT trial (NCT01103323), regorafenib significantly improved overall survival versus placebo in patients with treatment-refractory metastatic colorectal cancer. Of the 760 patients in CORRECT, 111 were Asian (mostly Japanese). This phase 3 trial was done to assess regorafenib in a broader population of Asian patients with refractory metastatic colorectal cancer than was studied in CORRECT.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Jun 2015

Volume: 16

Issue: 6

Affiliations

[1 ] Department of Medical Oncology, Fudan University Shanghai Cancer Center, and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

[2 ] Department of Medical Oncology, Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China.

[3 ] Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

[4 ] Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.

[5 ] Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China.

[6 ] Medical Oncology, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou, China.

[7 ] Beijing 307 People's Liberation Army Hospital Cancer Centre, Beijing, China.

[8 ] Third Affiliated Hospital of Harbin Medical University, Harbin, China.

[9 ] Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.

[10 ] Comprehensive Cancer Center, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China.

[11 ] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

[12 ] Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China.

[13 ] Jilin Provincial Tumor Hospital, Changchun, China.

[14 ] Department of Oncology, Cho Ray Hospital, Ho Chi Minh City, Vietnam.

[15 ] Department of Surgery, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan.

[16 ] Department of Medical Oncology, Zhong Shan Hospital, Fudan University, Shanghai, China.

[17 ] Department of Medical Oncology, Guangdong General Hospital, Guangzhou, Guangdong, China.

[18 ] Bayer Pharma AG, Berlin, Germany.

[19 ] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, South Korea. Electronic address: twkimmd@amc.seoul.kr.

Article

Publisher Item ID: S1470-2045(15)70156-7

DOI: 10.1016/S1470-2045(15)70156-7

PubMed ID: 25981818

SO-VID: 5c91948c-c9a4-44e9-b2b9-ba0adca8a740

History

Data availability:

Comments

Comment on this article

scite_

Cited by 265

See all cited by

- Version 1